Proteomics International Laboratories Ltd (ASX:PIQ)

Market Cap	19.00M -70.2%
Revenue (ttm)	3.21M -8.1%
Net Income	-9.66M
EPS	-0.07
Shares Out	165.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,844
Open	0.1200
Previous Close	0.1200
Day's Range	0.1150 - 0.1200
52-Week Range	0.1150 - 0.8600
Beta	-0.35
Analysts	Sell
Price Target	0.43 (+273.91%)
Earnings Date	Aug 21, 2026

About ASX:PIQ

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has comple...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PIQ

Financial Performance

In fiscal year 2025, ASX:PIQ's revenue was 3.31 million, an increase of 1.34% compared to the previous year's 3.27 million. Losses were -8.11 million, 27.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error